Fractyl Health (NASDAQ:GUTS) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Fractyl Health (NASDAQ:GUTS) released its quarterly earnings data on Tuesday. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02, Zacks reports. The business had revenue of $0.01 million during the quarter.

Fractyl Health Price Performance

Fractyl Health stock opened at $2.09 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 7.46 and a current ratio of 5.58. Fractyl Health has a twelve month low of $1.74 and a twelve month high of $14.50. The company’s 50-day moving average price is $2.61 and its 200-day moving average price is $4.04.

Insider Activity

In other news, CEO Harith Rajagopalan sold 96,517 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $2.47, for a total value of $238,396.99. Following the transaction, the chief executive officer now directly owns 491,329 shares in the company, valued at approximately $1,213,582.63. This represents a 16.42 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Jay David Caplan sold 64,197 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $2.47, for a total transaction of $158,566.59. Following the completion of the transaction, the insider now owns 153,544 shares in the company, valued at $379,253.68. This represents a 29.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 225,714 shares of company stock valued at $585,464 in the last ninety days.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.